Want to see PETV full AI Analyst Report?
PETV Stock Chart & Stats
$0.64
<$0.01(1.20%)
At close: 4:00 PM EDT
$0.64
<$0.01(1.20%)
Day’s Range― - ―
52-Week Range$0.59 - $1.69
Previous CloseN/A
Volume3.52K
Average Volume (3M)9.83K
Market Cap
$25.81M
Enterprise Value$31.52
Total Cash (Recent Filing)$122.63K
Total Debt (Recent Filing)$515.11K
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding37,950,497
10 Day Avg. Volume8,678
30 Day Avg. Volume9,834
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)9.60
Price to Sales (P/S)18.49
P/FCF Ratio-3.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And High Product MarginsRevenue growth and a mix shift toward proprietary Spryng support a stronger unit-economics profile. Sustained adoption could lift gross margins and improve operating leverage, although the company must scale sales materially before these benefits can offset its fixed cost base.
Regulatory And Clinical ValidationInternational regulatory recognition expands the addressable market and provides a durable commercialization milestone. Continued publications and animal studies can strengthen veterinarian confidence, support distributor adoption, and reduce barriers to entering additional markets over time.
AI And Platform ExpansionThe AI platform could add a recurring, high-margin revenue stream alongside the device business. Lower acquisition costs may improve commercial scalability, while the reported accuracy supports initial product credibility, though successful launch and recurring customer adoption remain necessary.
Bears Say
Very Small Revenue Base And Persistent LossesThe company has not yet demonstrated operating leverage: expenses substantially exceed revenue despite reported growth and improving losses. The small absolute sales base makes profitability highly dependent on rapid commercialization, leaving the business structurally fragile over the next several quarters.
Heavy Cash Burn And Limited LiquidityPersistent negative cash generation and minimal cash reserves constrain the ability to fund clinical work, sales expansion, and product development internally. Unless cash conversion improves or new capital arrives, funding needs could interrupt execution and weaken negotiating flexibility.
Dependence On Financing And Transaction ExecutionGrowth plans rely on external funding that is not yet fully secured, creating dilution and execution risk. The PBM transaction also depends on financing and closing conditions, while grant reliance adds uncertainty to the timing and scale of planned technology and clinical investments.
PetVivo Holdings News
PETV FAQ
What was PetVivo Holdings’s price range in the past 12 months?
PetVivo Holdings lowest stock price was $0.59 and its highest was $1.69 in the past 12 months.
What is PetVivo Holdings’s market cap?
PetVivo Holdings’s market cap is $25.81M.
When is PetVivo Holdings’s upcoming earnings report date?
PetVivo Holdings’s upcoming earnings report date is Nov 18, 2026 which is in 76 days.
How were PetVivo Holdings’s earnings last quarter?
PetVivo Holdings released its earnings results on Aug 14, 2026. The company reported -$0.047 earnings per share for the quarter.
Is PetVivo Holdings overvalued?
According to Wall Street analysts PetVivo Holdings’s price is currently Overvalued.
Does PetVivo Holdings pay dividends?
PetVivo Holdings does not currently pay dividends.
What is PetVivo Holdings’s EPS estimate?
PetVivo Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PetVivo Holdings have?
PetVivo Holdings has 37,950,497 shares outstanding.
What happened to PetVivo Holdings’s price movement after its last earnings report?
PetVivo Holdings reported an EPS of -$0.047 in its last earnings report. Following the earnings report the stock price went up 0.294%.
Which hedge fund is a major shareholder of PetVivo Holdings?
Currently, no hedge funds are holding shares in PETV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PetVivo Holdings
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
PETV Company Deck
PETV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful commercial, product and technological progress — including double-digit revenue growth, margin improvement, international regulatory recognition, strong AI beta results, and strategic M&A and partnership activity. However, the company remains small in absolute revenue, continues to report operating and net losses, has a tight cash balance ($123k) and depends on pending financing and grants (including a referenced $5M raise to close the PBM acquisition). The positives around product validation, high-margin pipeline opportunities and operational improvements are balanced by liquidity, financing and execution risks.View all PETV earnings summariesTechnical Analysis
Ownership Overview
39.38% Insiders
0.34% Other Institutional Investors
60.29% Public Companies and
Individual Investors